Harvard Bioscience, Inc.
HBIO
$0.489
$0.01292.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.24% | -14.41% | -16.14% | -13.15% | -11.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.24% | -14.41% | -16.14% | -13.15% | -11.36% |
| Cost of Revenue | -8.50% | -10.90% | -14.25% | -11.31% | -13.51% |
| Gross Profit | -14.87% | -16.87% | -17.45% | -14.39% | -9.78% |
| SG&A Expenses | -13.53% | -9.44% | -6.63% | -4.19% | -2.10% |
| Depreciation & Amortization | -9.22% | -7.09% | -4.89% | -6.64% | -9.48% |
| Other Operating Expenses | -79.12% | -97.52% | -- | -- | -- |
| Total Operating Expenses | -12.27% | -11.44% | -9.50% | -6.31% | -6.49% |
| Operating Income | 13.07% | -195.69% | -307.94% | -252.25% | -341.67% |
| Income Before Tax | -503.98% | -602.98% | -356.38% | -469.64% | -45.67% |
| Income Tax Expenses | -63.41% | -84.30% | -13.85% | -3.81% | 219.64% |
| Earnings from Continuing Operations | -437.61% | -564.88% | -263.25% | -336.44% | -96.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -437.61% | -564.88% | -263.25% | -336.44% | -96.68% |
| EBIT | 13.07% | -195.69% | -307.94% | -252.25% | -341.67% |
| EBITDA | 7.37% | -54.79% | -79.26% | -76.63% | -65.14% |
| EPS Basic | -427.24% | -549.88% | -256.95% | -326.79% | -90.52% |
| Normalized Basic EPS | -4.52% | -33.79% | -406.67% | -2,844.90% | -94.22% |
| EPS Diluted | -421.33% | -541.03% | -234.89% | -299.03% | -85.80% |
| Normalized Diluted EPS | -5.29% | -34.66% | -405.29% | -2,729.41% | -93.39% |
| Average Basic Shares Outstanding | 1.97% | 2.16% | 2.53% | 2.33% | 2.42% |
| Average Diluted Shares Outstanding | 2.43% | 2.63% | 2.59% | 1.93% | 2.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |